COMPANY
Peptilogics is a clinical stage company advancing its lead engineered peptide, PLG0206, a novel anti-biofilm therapeutic, for the treatment and prevention of devastating and costly medical device-related infections.
Peptilogics is headquartered in Pittsburgh, Pennsylvania, and is built on the ideals of fearless adventuring, unending inventiveness and curiosity, and taking our work, but not ourselves, very seriously.
CEO & Founder
Chief Operating Officer
Chief Medical Officer
Chief Development Officer
Chief Technology Officer
VP of People
CEO & Founder
VP of People
Chief Technology Officer
Chief Operating Officer
President, CEO & Founder
Peptilogics
Director
PreSight Capital
Managing Director & Chief Medical Officer
Thiel Capital
Director
Thiel Capital
Chief Investment Officer
AMR Action Fund
Global investment firm of Peter Thiel
Europe and US-based life science & technology fund
Leading international technology investment fund
Global venture fund focusing on anti-microbial therapeutics
Clinical Advisor, Orthopedics
Clinical Advisor, Orthopedics
Clinical Advisor, PJI
Clinical Advisor, Orthopedics
ID Physician, PJI Focus
Clinical Advisor, Orthopedics
Drug Development
Microbiology
Drug Development
& Pharmacology
We are always speaking with innovative partners to help translate great science into important medicines.
Email us at partners@peptilogics.com to explore partnership opportunities with Peptilogics.
Peptilogics and CARB-X have established a long-lasting relationship with shared goals. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world. CARB-X is the only global partnership that integrates solutions for the prevention, diagnosis and treatment of life-threatening bacterial infections, translating innovation from basic research to first-in-human clinical trials.
CARB-X is supporting the advancement of a controlled-release formulation of PLG0206 intended for use in preventing infection after high-energy-traumatic bone injuries.
